Inventor
HOERR INGMAR
DE21 patents
⚠️ This page may combine multiple inventors who share the name “HOERR INGMAR”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CUREVAC AG
11 patentsUS11078247B2Aug 3, 2021
RNA encoding a therapeutic protein
CUREVAC AG57 citations98
US11135312B2Oct 5, 2021
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
CUREVAC AG35 citations97
US10568972B2Feb 25, 2020
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
CUREVAC AG35 citations97
US9655955B2May 23, 2017
Application of mRNA for use as a therapeutic against tumour diseases
CUREVAC AG42 citations97
US9463228B2Oct 11, 2016
Application of mRNA for use as a therapeutic against tumour diseases
CUREVAC AG28 citations97
US9439956B2Sep 13, 2016
Application of mRNA for use as a therapeutic against tumour diseases
CUREVAC AG29 citations97
US9433670B2Sep 6, 2016
Application of mRNA for use as a therapeutic against tumour diseases
CUREVAC AG29 citations97
US9433669B2Sep 6, 2016
Application of mRNA for use as a therapeutic against tumor diseases
CUREVAC AG29 citations97
US10434154B2Oct 8, 2019
Composition for treating prostate cancer (PCa)
CUREVAC AG29 citations93
US9402887B2Aug 2, 2016
Composition for treating prostate cancer (PCa)
CUREVAC AG30 citations93
US11369691B2Jun 28, 2022
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
CUREVAC AG11 citations85
HOERR INGMAR
3 patentsUS8217016B2Jul 10, 2012
Application of mRNA for use as a therapeutic agent for tumorous diseases
HOERR INGMAR195 citations96
US10441653B2Oct 15, 2019
Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant
HOERR INGMAR29 citations90
US11421038B2Aug 23, 2022
RNA-coded antibody
HOERR INGMAR12 citations85